KPV: The Anti-Inflammatory Tripeptide and Its Role in Gut Health

KPV is a tripeptide derived from the C-terminal sequence of alpha-MSH. Where the parent molecule has broad melanocortin activity, KPV retains the anti-inflammatory properties in a far smaller, more stable form — making it one of the most studied peptides for gastrointestinal inflammation.

By UAE Peptide Clinic Research Desk

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-MSH (alpha-melanocyte-stimulating hormone). Where alpha-MSH is a 13-amino-acid peptide with broad melanocortin activity, KPV retains the anti-inflammatory properties of its parent molecule in a far smaller and more stable form. It is one of the most studied peptides for gastrointestinal inflammation, with demonstrated efficacy in inflammatory bowel disease models.

Mechanism of Action

KPV exerts its anti-inflammatory effects through multiple pathways: it inhibits pro-inflammatory cytokine production (including IL-6, TNF-alpha, and IL-1beta), activates melanocortin receptors at peripheral and intestinal sites, and directly modulates NF-kB signalling — a master regulator of the inflammatory response. Its direct intestinal action makes it particularly relevant for conditions of gut inflammation, where systemic immunosuppression would be an unnecessarily broad intervention.

Clinical Applications

KPV is used in physician-supervised protocols for inflammatory bowel conditions (Crohn's disease, ulcerative colitis), gut permeability and intestinal barrier support, and systemic inflammatory conditions. Its small size allows oral delivery with localised intestinal action — though systemic administration is also studied. It complements BPC-157 in gut-repair protocols.

KPV is available for patients with documented inflammatory conditions under physician supervision. Our physicians will review your inflammatory markers and gastrointestinal history before recommending. Book a consultation at /book.